We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+7.61%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$22.7M
Cap. Flow
+$19.2M
Cap. Flow %
3.83%
Top 10 Hldgs %
48.75%
Holding
84
New
17
Increased
18
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$38.4M
2
ISRG icon
Intuitive Surgical
ISRG
+$14.2M
3
RGEN icon
Repligen
RGEN
+$13.6M
4
GMAB icon
Genmab
GMAB
+$13.3M
5
HNGE
Hinge Health
HNGE
+$13M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
2
HUM icon
Humana
HUM
+$13.3M
3
GKOS icon
Glaukos
GKOS
+$13.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.93M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
2 Miscellaneous 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.61B
$39M 7.77%
1,499,942
+519,000
+53% +$12.5M
BSX icon
2
Boston Scientific
BSX
$62.8B
$34.6M 6.89%
321,800
-14,200
-4% -$1.44M
NTRA icon
3
Natera
NTRA
$53.2B
$33.7M 6.71%
199,300
+80,100
+67% +$12.5M
DNTH icon
4
Dianthus Therapeutics
DNTH
$5.42B
$32.5M 6.47%
1,742,902
+22,000
+1% +$413K
EXAS
5
DELISTED
Exact Sciences
EXAS
$18.9M 3.76%
355,000
+2,000
+0.6% +$102K
THC icon
6
Tenet Healthcare
THC
$21.1B
$18.7M 3.72%
106,000
+34,000
+47% +$5.12M
DXCM icon
7
DexCom
DXCM
$33.7B
$18.4M 3.66%
210,500
+30,500
+17% +$2.39M
DHR icon
8
Danaher
DHR
$149B
$17.7M 3.53%
89,700
+45,200
+102% +$8.77M
HNGE
9
Hinge Health
HNGE
$7.66B
$16.7M 3.32%
+322,344
New +$13M
ISRG icon
10
Intuitive Surgical
ISRG
$139B
$14.7M 2.93%
+27,100
New +$14.2M
GMAB icon
11
Genmab
GMAB
$21.4B
$13.4M 2.68%
+650,000
New +$13.3M
RGEN icon
12
Repligen
RGEN
$9.98B
$13.2M 2.64%
+106,500
New +$13.6M
TMO icon
13
Thermo Fisher Scientific
TMO
$241B
$12M 2.39%
29,600
+14,100
+91% +$5.9M
TEVA icon
14
Teva Pharmaceutical Industries Limited
TEVA
$45.5B
$11.6M 2.3%
689,500
+208,500
+43% +$3.36M
JBIO
15
Jade Biosciences
JBIO
$1.08B
$11.3M 2.24%
+1,127,186
New +$38.4M
PHAT icon
16
Phathom Pharmaceuticals
PHAT
$605M
$10.2M 2.03%
1,064,500
+264,500
+33% +$1.46M
UNH icon
17
UnitedHealth
UNH
$338B
$9.98M 1.99%
32,000
-18,500
-37% -$7.07M
MCK icon
18
McKesson
MCK
$102B
$9.89M 1.97%
+13,500
New +$9.53M
AXSM icon
19
Axsome Therapeutics
AXSM
$10.9B
$9.86M 1.97%
94,500
+17,500
+23% +$1.85M
COR icon
20
Cencora
COR
$58.9B
$9.84M 1.96%
32,800
-6,500
-17% -$1.87M
HQY icon
21
HealthEquity
HQY
$7.87B
$9.64M 1.92%
92,000
+14,000
+18% +$1.33M
EHC icon
22
Encompass Health
EHC
$12B
$9.07M 1.81%
+74,000
New +$8.45M
RVMD icon
23
Revolution Medicines
RVMD
$40.9B
$8.41M 1.68%
228,600
+15,600
+7% +$599K
AKRO
24
DELISTED
Akero Therapeutics
AKRO
$7.15M 1.42%
134,000
+77,000
+135% +$3.5M
OMDA
25
Omada Health Inc
OMDA
$1.25B
$7.15M 1.42%
+390,600
New +$6.76M
1
2 3 4

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q2 2025 Portfolio in Review

As of Q2 2025, Avidity Partners Management held 84 positions worth $502M, down 4.3% from $525M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Avidity Partners Management deployed $19.2M of net new capital in Q2 2025, opening 17 new positions and adding to 18 existing holdings. Its largest new stake was Jade Biosciences: 1,127,186 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 91% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Humana, an estimated $13.3M trimmed.

  • Avidity Partners Management's largest Q2 2025 buy was Jade Biosciences: 1,127,186 shares worth $11.3M.
  • Avidity Partners Management added most to CG Oncology in Q2 2025, an estimated $12.5M increase.
  • Avidity Partners Management's biggest Q2 2025 reduction was Humana, cutting an estimated $13.3M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q2 2025, selling an estimated $16.1M.
  • Avidity Partners Management's ten largest holdings make up 49% of its $502M portfolio in Q2 2025.
  • Avidity Partners Management opened 17 new positions and closed 28 in Q2 2025.
  • Avidity Partners Management's portfolio value fell 4.3% quarter-over-quarter to $502M.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.